https://spypharm.com/rss/category/pharmaceutical SpyPharm | Pharmaceutical News, Developments & Trends & : Pharmaceutical en Copyright 2023 Spypharm & All Rights Reserved. https://spypharm.com/fda-approves-amgens-combo-therapy-for-colorectal-cancer https://spypharm.com/fda-approves-amgens-combo-therapy-for-colorectal-cancer Mon, 20 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/leading-sales-and-marketing-intent-data-database-and-data-enrichment-providers-and-technology-solutions-for-the-pharmaceutical-industry https://spypharm.com/leading-sales-and-marketing-intent-data-database-and-data-enrichment-providers-and-technology-solutions-for-the-pharmaceutical-industry Mon, 20 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/novo-nordisks-ozempic-named-in-latest-medicare-price-negotiations https://spypharm.com/novo-nordisks-ozempic-named-in-latest-medicare-price-negotiations Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/fda-beats-ema-to-most-approved-new-drugs-in-2024 https://spypharm.com/fda-beats-ema-to-most-approved-new-drugs-in-2024 Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pfizer-believes-in-the-metaverse-will-healthcare-thaw-the-technologys-winter https://spypharm.com/pfizer-believes-in-the-metaverse-will-healthcare-thaw-the-technologys-winter Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/heor-explained-improving-healthcare-decisions-with-real-world-evidence https://spypharm.com/heor-explained-improving-healthcare-decisions-with-real-world-evidence Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/mega-ma-at-jp-morgan-conference-2025-is-biopharma-ma-poised-for-a-rebound https://spypharm.com/mega-ma-at-jp-morgan-conference-2025-is-biopharma-ma-poised-for-a-rebound Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/charles-river-and-akron-link-to-integrate-cytokines-into-cell-therapy https://spypharm.com/charles-river-and-akron-link-to-integrate-cytokines-into-cell-therapy Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/copd-market-to-expand-with-astrazenecas-focus-on-biologics-and-strong-portfolio-growth https://spypharm.com/copd-market-to-expand-with-astrazenecas-focus-on-biologics-and-strong-portfolio-growth Sat, 18 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/impact-ovarian-cancer-capsules-authorised-in-china https://spypharm.com/impact-ovarian-cancer-capsules-authorised-in-china Sat, 18 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/jpm-2025-lonza-shares-outlook-on-chi-exit-and-acquisition-strategy https://spypharm.com/jpm-2025-lonza-shares-outlook-on-chi-exit-and-acquisition-strategy Sat, 18 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/shionogi-awarded-375m-from-hhs-for-preventative-covid-19-injectable https://spypharm.com/shionogi-awarded-375m-from-hhs-for-preventative-covid-19-injectable Sat, 18 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody https://spypharm.com/abbvie-and-simcere-zaiming-link-to-develop-trispecific-antibody Thu, 16 Jan 2025 06:00:22 -0500 spectro https://spypharm.com/jp-morgan-2025-incyte-expects-period-of-defining-catalysts https://spypharm.com/jp-morgan-2025-incyte-expects-period-of-defining-catalysts Thu, 16 Jan 2025 06:00:22 -0500 spectro https://spypharm.com/bringing-engineering-to-a-new-level-zetas-integrated-approach https://spypharm.com/bringing-engineering-to-a-new-level-zetas-integrated-approach Thu, 16 Jan 2025 06:00:22 -0500 spectro https://spypharm.com/jp-morgan-2025-astrazeneca-promises-a-catalyst-rich-year-ahead https://spypharm.com/jp-morgan-2025-astrazeneca-promises-a-catalyst-rich-year-ahead Thu, 16 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/regenxbio-and-nippon-shinyaku-forge-810m-gene-therapy-deal https://spypharm.com/regenxbio-and-nippon-shinyaku-forge-810m-gene-therapy-deal Thu, 16 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/insmeds-gene-therapy-poised-to-challenge-dmd-landscape-after-ind-clearance https://spypharm.com/insmeds-gene-therapy-poised-to-challenge-dmd-landscape-after-ind-clearance Thu, 16 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/lilly-gains-us-fda-approval-for-omvoh-to-treat-crohns-disease https://spypharm.com/lilly-gains-us-fda-approval-for-omvoh-to-treat-crohns-disease Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/be-bio-secures-92m-for-haemophilia-b-and-hypophosphatasia-treatments https://spypharm.com/be-bio-secures-92m-for-haemophilia-b-and-hypophosphatasia-treatments Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/jp-morgan-2025-abbvie-counts-on-skyrizi-and-rinvoq-to-fill-humira-sized-hole https://spypharm.com/jp-morgan-2025-abbvie-counts-on-skyrizi-and-rinvoq-to-fill-humira-sized-hole Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/charles-river-ceo-reveals-drop-in-2025-revenue-outlook-at-jp-morgan https://spypharm.com/charles-river-ceo-reveals-drop-in-2025-revenue-outlook-at-jp-morgan Thu, 16 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/biogen-proposes-acquisition-of-partner-sage-therapeutics https://spypharm.com/biogen-proposes-acquisition-of-partner-sage-therapeutics Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/gilead-and-leo-pharma-link-on-programmes-for-inflammatory-conditions https://spypharm.com/gilead-and-leo-pharma-link-on-programmes-for-inflammatory-conditions Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/pfizer-pitches-pipeline-priorities-in-oncology-and-obesity-at-jp-morgan-2025 https://spypharm.com/pfizer-pitches-pipeline-priorities-in-oncology-and-obesity-at-jp-morgan-2025 Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/jp-morgan-2025-nvidia-partners-with-iqvia-illumina-and-mayo-clinic https://spypharm.com/jp-morgan-2025-nvidia-partners-with-iqvia-illumina-and-mayo-clinic Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/small-matter-big-challenges-nano-milling-in-a-sterilised-environment https://spypharm.com/small-matter-big-challenges-nano-milling-in-a-sterilised-environment Tue, 14 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/enhancing-patient-engagement-and-outcomes-in-the-nhs https://spypharm.com/enhancing-patient-engagement-and-outcomes-in-the-nhs Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-syngene https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-syngene Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-iff-pharma-solutions https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-iff-pharma-solutions Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-image-analysis-group https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-image-analysis-group Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/eli-lilly-targets-scorpion-therapeutics-to-expand-reach-in-oncology https://spypharm.com/eli-lilly-targets-scorpion-therapeutics-to-expand-reach-in-oncology Tue, 14 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/fda-cder-director-patrizia-cavazzoni-announces-resignation https://spypharm.com/fda-cder-director-patrizia-cavazzoni-announces-resignation Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/climb-bio-enters-licensing-deal-with-mabworks-for-clym116-development https://spypharm.com/climb-bio-enters-licensing-deal-with-mabworks-for-clym116-development Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/coave-therapeutics-raises-33m-in-funding-to-advance-aligater-platform https://spypharm.com/coave-therapeutics-raises-33m-in-funding-to-advance-aligater-platform Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/alzheimers-total-prevalent-cases-to-reach-2251-million-in-8mm-in-2033 https://spypharm.com/alzheimers-total-prevalent-cases-to-reach-2251-million-in-8mm-in-2033 Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/a2-biotherapeutics-raises-80m-to-advance-car-t-therapies-for-solid-tumours https://spypharm.com/a2-biotherapeutics-raises-80m-to-advance-car-t-therapies-for-solid-tumours Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/light-horse-emerges-with-62m-and-novartis-partnership-worth-up-to-1bn https://spypharm.com/light-horse-emerges-with-62m-and-novartis-partnership-worth-up-to-1bn Sun, 12 Jan 2025 06:00:12 -0500 spectro https://spypharm.com/novo-nordisk-and-valo-expand-cardiometabolic-drug-partnership https://spypharm.com/novo-nordisk-and-valo-expand-cardiometabolic-drug-partnership Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/sanofi-taps-alloy-therapeutics-for-cns-antisense-drug-development https://spypharm.com/sanofi-taps-alloy-therapeutics-for-cns-antisense-drug-development Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/clinical-trial-trends-in-2025-investment-headwinds-wearables-and-targeted-ai-uses https://spypharm.com/clinical-trial-trends-in-2025-investment-headwinds-wearables-and-targeted-ai-uses Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/msds-hpv-vaccine-gains-china-nmpas-expanded-approval-for-males https://spypharm.com/msds-hpv-vaccine-gains-china-nmpas-expanded-approval-for-males Fri, 10 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/newron-and-myung-in-pharm-sign-agreement-for-evenamide-development https://spypharm.com/newron-and-myung-in-pharm-sign-agreement-for-evenamide-development Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/samsung-biologics-and-ligachem-extend-adc-services-deal https://spypharm.com/samsung-biologics-and-ligachem-extend-adc-services-deal Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/aspect-biosystems-secures-115m-to-develop-tissue-therapeutics https://spypharm.com/aspect-biosystems-secures-115m-to-develop-tissue-therapeutics Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/synaffix-secures-adc-deals-with-boehringer-and-mitsubishi-tanabe https://spypharm.com/synaffix-secures-adc-deals-with-boehringer-and-mitsubishi-tanabe Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate https://spypharm.com/uk-based-verdiva-launches-with-410m-and-an-oral-glp-1ra-candidate Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/palforzias-peanut-allergy-treatment-use-in-europe-expanded-to-toddlers https://spypharm.com/palforzias-peanut-allergy-treatment-use-in-europe-expanded-to-toddlers Fri, 10 Jan 2025 06:00:16 -0500 spectro https://spypharm.com/covid-19-the-global-clinical-trial-landscape-in-2024 https://spypharm.com/covid-19-the-global-clinical-trial-landscape-in-2024 Wed, 08 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/danish-biotech-orbis-secures-94m-to-develop-oral-versions-of-biologics https://spypharm.com/danish-biotech-orbis-secures-94m-to-develop-oral-versions-of-biologics Wed, 08 Jan 2025 06:00:19 -0500 spectro https://spypharm.com/fda-awards-gsa-breakthrough-status-for-relapsed-osteosarcoma-treatment https://spypharm.com/fda-awards-gsa-breakthrough-status-for-relapsed-osteosarcoma-treatment Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/candid-therapeutics-signs-925m-t-cell-engager-deal-with-wuxi-biologics https://spypharm.com/candid-therapeutics-signs-925m-t-cell-engager-deal-with-wuxi-biologics Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/fda-accepts-sentynls-menkes-disease-therapy-nda-for-priority-review https://spypharm.com/fda-accepts-sentynls-menkes-disease-therapy-nda-for-priority-review Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/fda-grants-odd-to-tempests-hepatocellular-carcinoma-treatment https://spypharm.com/fda-grants-odd-to-tempests-hepatocellular-carcinoma-treatment Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/calls-for-increased-education-and-support-for-sickle-cell-blood-therapy-in-us https://spypharm.com/calls-for-increased-education-and-support-for-sickle-cell-blood-therapy-in-us Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/acelyrin-stock-plunges-after-positive-phase-ii-data-readout-in-thyroid-eye-disease https://spypharm.com/acelyrin-stock-plunges-after-positive-phase-ii-data-readout-in-thyroid-eye-disease Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/variant-bio-and-novo-nordisk-to-identify-targets-for-metabolic-disease-treatment https://spypharm.com/variant-bio-and-novo-nordisk-to-identify-targets-for-metabolic-disease-treatment Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/wuxi-biologics-to-sell-ireland-based-vaccine-site-to-msd-for-500m https://spypharm.com/wuxi-biologics-to-sell-ireland-based-vaccine-site-to-msd-for-500m Wed, 08 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/gcc-4001-by-artiva-biotherapeutics-for-rheumatoid-arthritis-likelihood-of-approval https://spypharm.com/gcc-4001-by-artiva-biotherapeutics-for-rheumatoid-arthritis-likelihood-of-approval Mon, 06 Jan 2025 06:00:21 -0500 spectro https://spypharm.com/hlc-001-by-human-life-cord-japan-for-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval https://spypharm.com/hlc-001-by-human-life-cord-japan-for-coronavirus-disease-2019-covid-19-associated-acute-respiratory-distress-syndrome-likelihood-of-approval Mon, 06 Jan 2025 06:00:20 -0500 spectro https://spypharm.com/cd19-cd22-car-t-cells-by-shanghai-biomed-union-biotechnology-for-unspecified-b-cell-lymphomas-likelihood-of-approval https://spypharm.com/cd19-cd22-car-t-cells-by-shanghai-biomed-union-biotechnology-for-unspecified-b-cell-lymphomas-likelihood-of-approval Mon, 06 Jan 2025 06:00:18 -0500 spectro https://spypharm.com/nmda-regulator-by-boehringer-ingelheim-international-for-unspecified-central-nervous-system-disorders-likelihood-of-approval https://spypharm.com/nmda-regulator-by-boehringer-ingelheim-international-for-unspecified-central-nervous-system-disorders-likelihood-of-approval Mon, 06 Jan 2025 06:00:17 -0500 spectro https://spypharm.com/paclitaxel-by-innoup-farma-for-solid-tumor-likelihood-of-approval https://spypharm.com/paclitaxel-by-innoup-farma-for-solid-tumor-likelihood-of-approval Mon, 06 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/fosigotifator-by-calico-life-sciences-for-unspecified-central-nervous-system-disorders-likelihood-of-approval https://spypharm.com/fosigotifator-by-calico-life-sciences-for-unspecified-central-nervous-system-disorders-likelihood-of-approval Mon, 06 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/coronavirus-disease-2019-covid-19-vaccine-by-china-national-biotec-group-for-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval https://spypharm.com/coronavirus-disease-2019-covid-19-vaccine-by-china-national-biotec-group-for-coronavirus-disease-2019-covid-19-pneumonia-likelihood-of-approval Mon, 06 Jan 2025 06:00:13 -0500 spectro https://spypharm.com/abu-dhabi-stem-cells-center-develops-clinical-grade-ipscs https://spypharm.com/abu-dhabi-stem-cells-center-develops-clinical-grade-ipscs Mon, 06 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/chinas-nmpa-approves-gsks-nucala-for-crswnp-treatment https://spypharm.com/chinas-nmpa-approves-gsks-nucala-for-crswnp-treatment Mon, 06 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/bnt-325-by-biontech-for-malignant-mesothelioma-likelihood-of-approval https://spypharm.com/bnt-325-by-biontech-for-malignant-mesothelioma-likelihood-of-approval Mon, 06 Jan 2025 06:00:11 -0500 spectro https://spypharm.com/neumora-shares-sink-following-phase-iii-flop-in-mdd https://spypharm.com/neumora-shares-sink-following-phase-iii-flop-in-mdd Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/uk-mhra-approves-msds-pulmonary-arterial-hypertension-therapy https://spypharm.com/uk-mhra-approves-msds-pulmonary-arterial-hypertension-therapy Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/the-unmet-need-in-t2-low-asthma-a-critical-gap-in-treatment https://spypharm.com/the-unmet-need-in-t2-low-asthma-a-critical-gap-in-treatment Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/leading-strategic-intelligence-solutions-for-the-pharmaceteutical-industry https://spypharm.com/leading-strategic-intelligence-solutions-for-the-pharmaceteutical-industry Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/tirzepatide-outpacing-wegovy-in-the-obesity-space https://spypharm.com/tirzepatide-outpacing-wegovy-in-the-obesity-space Sat, 04 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/expanding-diagnostic-and-biomarker-options-to-improve-mash-clinical-trials https://spypharm.com/expanding-diagnostic-and-biomarker-options-to-improve-mash-clinical-trials Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/from-davids-to-goliaths-the-glp-1ra-gold-rush https://spypharm.com/from-davids-to-goliaths-the-glp-1ra-gold-rush Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/sigas-antiviral-approved-in-japan-for-orthopoxvirus-treatment https://spypharm.com/sigas-antiviral-approved-in-japan-for-orthopoxvirus-treatment Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/iit-guwahati-and-bose-institute-develop-injectable-hydrogel-for-cancer https://spypharm.com/iit-guwahati-and-bose-institute-develop-injectable-hydrogel-for-cancer Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/chinas-nmpa-prioritises-hutchmeds-lung-cancer-therapy-review https://spypharm.com/chinas-nmpa-prioritises-hutchmeds-lung-cancer-therapy-review Sat, 04 Jan 2025 06:00:14 -0500 spectro https://spypharm.com/innovent-and-roche-link-on-lung-cancer-therapy-development https://spypharm.com/innovent-and-roche-link-on-lung-cancer-therapy-development Thu, 02 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/sangamos-stock-sinks-50-as-pfizer-halts-haemophilia-a-gene-therapy-partnership https://spypharm.com/sangamos-stock-sinks-50-as-pfizer-halts-haemophilia-a-gene-therapy-partnership Thu, 02 Jan 2025 06:00:15 -0500 spectro https://spypharm.com/tevimbra-by-beigene-for-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval https://spypharm.com/tevimbra-by-beigene-for-muscle-invasive-bladder-cancer-mibc-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/tevimbra-by-beigene-for-gallbladder-cancer-likelihood-of-approval https://spypharm.com/tevimbra-by-beigene-for-gallbladder-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/ct-7439-by-carrick-therapeutics-for-breast-cancer-likelihood-of-approval https://spypharm.com/ct-7439-by-carrick-therapeutics-for-breast-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/iptacopan-hydrochloride-by-novartis-for-granulomatosis-with-polyangiitis-wegeners-granulomatosis-likelihood-of-approval https://spypharm.com/iptacopan-hydrochloride-by-novartis-for-granulomatosis-with-polyangiitis-wegeners-granulomatosis-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-metastatic-colorectal-cancer-likelihood-of-approval https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-metastatic-colorectal-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-pancreatic-ductal-adenocarcinoma-likelihood-of-approval https://spypharm.com/itm-91-by-itm-isotope-technologies-munich-for-pancreatic-ductal-adenocarcinoma-likelihood-of-approval Tue, 31 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/tebapivat-by-agios-pharmaceuticals-for-sickle-cell-disease-likelihood-of-approval https://spypharm.com/tebapivat-by-agios-pharmaceuticals-for-sickle-cell-disease-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/lxe-408-by-novartis-for-chagas-disease-american-trypanosomiasis-likelihood-of-approval https://spypharm.com/lxe-408-by-novartis-for-chagas-disease-american-trypanosomiasis-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/xaluritamig-by-amgen-for-prostate-cancer-likelihood-of-approval https://spypharm.com/xaluritamig-by-amgen-for-prostate-cancer-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/nvp-1805r2-by-nvp-healthcare-for-unspecified-cardiovascular-disorders-likelihood-of-approval https://spypharm.com/nvp-1805r2-by-nvp-healthcare-for-unspecified-cardiovascular-disorders-likelihood-of-approval Tue, 31 Dec 2024 06:00:14 -0500 spectro https://spypharm.com/tricaprilin-by-cerecin-for-infantile-spasm-west-syndrome-likelihood-of-approval https://spypharm.com/tricaprilin-by-cerecin-for-infantile-spasm-west-syndrome-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/nelivaptan-by-hmnc-for-major-depressive-disorder-likelihood-of-approval https://spypharm.com/nelivaptan-by-hmnc-for-major-depressive-disorder-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/darigabat-by-cerevel-therapeutics-for-seizures-likelihood-of-approval https://spypharm.com/darigabat-by-cerevel-therapeutics-for-seizures-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-osteosarcoma-likelihood-of-approval https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-osteosarcoma-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-sarcomas-likelihood-of-approval https://spypharm.com/gene-therapy-to-target-gd2-for-oncology-by-bristol-myers-squibb-for-sarcomas-likelihood-of-approval Fri, 27 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/stemvacs-v-by-res-nova-bio-for-metastatic-breast-cancer-likelihood-of-approval https://spypharm.com/stemvacs-v-by-res-nova-bio-for-metastatic-breast-cancer-likelihood-of-approval Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/lidocaine-by-medrx-for-postherpetic-neuralgia-likelihood-of-approval https://spypharm.com/lidocaine-by-medrx-for-postherpetic-neuralgia-likelihood-of-approval Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/kgyy-15-by-op-t-mune-for-type-1-diabetes-juvenile-diabetes-likelihood-of-approval https://spypharm.com/kgyy-15-by-op-t-mune-for-type-1-diabetes-juvenile-diabetes-likelihood-of-approval Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/mankind-pharma-and-innovent-partner-for-sintilimab-commercialisation-in-india https://spypharm.com/mankind-pharma-and-innovent-partner-for-sintilimab-commercialisation-in-india Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/eisbach-bio-positions-hrd-targeting-therapy-to-supplant-parp-inhibitors https://spypharm.com/eisbach-bio-positions-hrd-targeting-therapy-to-supplant-parp-inhibitors Fri, 27 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/investors-optimistic-about-continued-biotech-and-medtech-ipo-resurgence-in-2025 https://spypharm.com/investors-optimistic-about-continued-biotech-and-medtech-ipo-resurgence-in-2025 Wed, 25 Dec 2024 06:00:16 -0500 spectro https://spypharm.com/vertex-secures-two-fda-wins-for-cystic-fibrosis-both-with-boxed-warnings https://spypharm.com/vertex-secures-two-fda-wins-for-cystic-fibrosis-both-with-boxed-warnings Wed, 25 Dec 2024 06:00:16 -0500 spectro https://spypharm.com/eli-lillys-uk-life-sciences-investment-a-pivotal-moment-says-analyst https://spypharm.com/eli-lillys-uk-life-sciences-investment-a-pivotal-moment-says-analyst Wed, 25 Dec 2024 06:00:16 -0500 spectro https://spypharm.com/gemmabio-raises-34m-to-advance-gene-therapy-programmes https://spypharm.com/gemmabio-raises-34m-to-advance-gene-therapy-programmes Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/astrazenecas-tagrisso-gains-ec-approval-for-nsclc-treatment https://spypharm.com/astrazenecas-tagrisso-gains-ec-approval-for-nsclc-treatment Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/sk-bioscience-and-sanofi-expand-agreement-for-pneumococcal-conjugate-vaccines https://spypharm.com/sk-bioscience-and-sanofi-expand-agreement-for-pneumococcal-conjugate-vaccines Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/novo-gets-the-green-light-for-once-daily-haemophilia-drug-following-setbacks https://spypharm.com/novo-gets-the-green-light-for-once-daily-haemophilia-drug-following-setbacks Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/rapt-therapeutics-and-shanghai-jemincare-sign-anti-ige-antibody-agreement https://spypharm.com/rapt-therapeutics-and-shanghai-jemincare-sign-anti-ige-antibody-agreement Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/fda-approves-lillys-obesity-med-zepbound-to-treat-obstructive-sleep-apnoea https://spypharm.com/fda-approves-lillys-obesity-med-zepbound-to-treat-obstructive-sleep-apnoea Wed, 25 Dec 2024 06:00:15 -0500 spectro https://spypharm.com/pfizers-colorectal-cancer-combo-therapy-gains-accelerated-approval-from-fda https://spypharm.com/pfizers-colorectal-cancer-combo-therapy-gains-accelerated-approval-from-fda Mon, 23 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/astellas-and-sangamo-sign-capsid-deal-for-neurological-diseases https://spypharm.com/astellas-and-sangamo-sign-capsid-deal-for-neurological-diseases Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/vertexs-stock-hurt-after-non-opioid-pain-drug-shows-benefit-similar-to-placebo https://spypharm.com/vertexs-stock-hurt-after-non-opioid-pain-drug-shows-benefit-similar-to-placebo Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-mesoblasts-ryoncil-for-sr-agvhd-treatment https://spypharm.com/fda-approves-mesoblasts-ryoncil-for-sr-agvhd-treatment Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset https://spypharm.com/msd-makes-obesity-play-in-up-to-2bn-deal-for-hansohs-glp-1ra-asset Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/palleon-and-shanghai-henlius-biotech-link-on-autoimmune-therapy https://spypharm.com/palleon-and-shanghai-henlius-biotech-link-on-autoimmune-therapy Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/magazine-us-reproductive-laws-could-limit-womens-participation-in-clinical-trials https://spypharm.com/magazine-us-reproductive-laws-could-limit-womens-participation-in-clinical-trials Sat, 21 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-ionis-tryngolza-for-fcs-treatment https://spypharm.com/fda-approves-ionis-tryngolza-for-fcs-treatment Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss https://spypharm.com/novo-nordisk-takes-a-hit-as-cagrisema-underperforms-in-weight-loss Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation https://spypharm.com/fda-confirms-end-of-eli-lillys-tirzepatide-shortage-after-re-evaluation Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/setback-for-uk-pharma-as-government-sets-unexpectedly-high-vpag-payback-rate-in-2025 https://spypharm.com/setback-for-uk-pharma-as-government-sets-unexpectedly-high-vpag-payback-rate-in-2025 Sat, 21 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/oncology-rd-emerging-therapies-and-new-challenges https://spypharm.com/oncology-rd-emerging-therapies-and-new-challenges Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products https://spypharm.com/fda-targets-more-online-vendors-selling-unapproved-glp-1ra-products Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/gilead-and-terray-link-to-develop-small-molecule-therapies https://spypharm.com/gilead-and-terray-link-to-develop-small-molecule-therapies Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/egyptian-drug-authority-approves-lilly-and-evas-insulin-injection https://spypharm.com/egyptian-drug-authority-approves-lilly-and-evas-insulin-injection Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novo-nordisk-invests-12bn-in-new-denmark-facility https://spypharm.com/novo-nordisk-invests-12bn-in-new-denmark-facility Thu, 19 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novo-holdings-completes-catalent-acquisition-for-165bn https://spypharm.com/novo-holdings-completes-catalent-acquisition-for-165bn Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/pharmas-data-and-analytics-market-forecast-to-reach-to-21bn-by-2028 https://spypharm.com/pharmas-data-and-analytics-market-forecast-to-reach-to-21bn-by-2028 Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/abera-and-orexo-partner-for-vaccine-powder-formulations https://spypharm.com/abera-and-orexo-partner-for-vaccine-powder-formulations Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/the-healthcare-sector-must-change-its-industrial-refrigeration-methods-to-reduce-its-emissions https://spypharm.com/the-healthcare-sector-must-change-its-industrial-refrigeration-methods-to-reduce-its-emissions Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19 https://spypharm.com/petrovax-announces-positive-results-from-long-cov-iii-21-trial-of-longidaza-for-long-term-pulmonary-sequelae-of-covid-19 Thu, 19 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape https://spypharm.com/small-cell-lung-cancer-navigating-the-global-clinical-trial-landscape Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/denmarks-hta-evolution https://spypharm.com/denmarks-hta-evolution Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents https://spypharm.com/ema-recommends-expanding-approval-of-ofev-to-children-and-adolescents Tue, 17 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/bavarian-nordic-signs-mpox-vax-deal-with-serum-institute-of-india https://spypharm.com/bavarian-nordic-signs-mpox-vax-deal-with-serum-institute-of-india Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/cto-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts https://spypharm.com/cto-europe-2024-keep-the-burden-of-trials-away-from-patients-say-experts Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/gsks-lung-cancer-therapy-gains-ema-prime-designation https://spypharm.com/gsks-lung-cancer-therapy-gains-ema-prime-designation Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/adcs-breach-barriers-to-become-mainstream-cancer-treatment https://spypharm.com/adcs-breach-barriers-to-become-mainstream-cancer-treatment Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/fda-approves-galdermas-nemluvio-to-treat-atopic-dermatitis https://spypharm.com/fda-approves-galdermas-nemluvio-to-treat-atopic-dermatitis Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world https://spypharm.com/the-future-of-third-party-logistics-in-an-evolving-biopharmaceutical-world Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025 https://spypharm.com/reprieve-for-wuxi-as-biosecure-vote-likely-pushed-to-2025 Tue, 17 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-cullinan-therapeuticss-cln-619 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-cullinan-therapeuticss-cln-619 Sun, 15 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-avidity-biosciencess-aoc-1020 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-avidity-biosciencess-aoc-1020 Sun, 15 Dec 2024 06:00:13 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-in8bios-inb-400 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-in8bios-inb-400 Sun, 15 Dec 2024 06:00:12 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vigil-neurosciences-iluzanebart https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-vigil-neurosciences-iluzanebart Sun, 15 Dec 2024 06:00:12 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-aquestive-therapeuticss-epinephrine https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-aquestive-therapeuticss-epinephrine Sun, 15 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-jazz-pharmaceuticalss-jzp-898 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-jazz-pharmaceuticalss-jzp-898 Sun, 15 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-solid-biosciencess-sgt-003 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-solid-biosciencess-sgt-003 Sun, 15 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-forte-biosciencess-fb-102 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-forte-biosciencess-fb-102 Sun, 15 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-tenaya-therapeuticss-tn-401 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-tenaya-therapeuticss-tn-401 Sun, 15 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-131 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-crispr-therapeuticss-ctx-131 Sun, 15 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-i-mabs-lemzoparlimab https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-i-mabs-lemzoparlimab Fri, 13 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-clesacostat-tromethamine-ervogastat https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-pfizers-clesacostat-tromethamine-ervogastat Fri, 13 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-adicet-bios-adi-001 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-adicet-bios-adi-001 Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-eli-lilly-and-cos-imlunestrant-tosylate https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-eli-lilly-and-cos-imlunestrant-tosylate Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-novartiss-rapcabtagene-autoleucel https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-novartiss-rapcabtagene-autoleucel Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/flu-vaccine-strategy-on-the-line-as-new-us-leaders-anticipated-to-take-charge https://spypharm.com/flu-vaccine-strategy-on-the-line-as-new-us-leaders-anticipated-to-take-charge Fri, 13 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-rallybios-rlyb-116 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-rallybios-rlyb-116 Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/aim-immunotech-gains-netherlands-patent-for-post-covid-fatigue-therapy https://spypharm.com/aim-immunotech-gains-netherlands-patent-for-post-covid-fatigue-therapy Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-oric-pharmaceuticalss-oric-944 https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-oric-pharmaceuticalss-oric-944 Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-plus-therapeuticss-rhenium-186re-obisbemeda https://spypharm.com/risk-adjusted-net-present-value-what-is-the-current-valuation-of-plus-therapeuticss-rhenium-186re-obisbemeda Fri, 13 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/seres-ser-155-gains-breakthrough-status-for-bsis-reduction https://spypharm.com/seres-ser-155-gains-breakthrough-status-for-bsis-reduction Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fda-to-review-gsks-nucala-for-copd https://spypharm.com/fda-to-review-gsks-nucala-for-copd Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/new-amsterdam-stock-jumps-as-ldl-c-lowering-drug-scores-again-at-phase-iii https://spypharm.com/new-amsterdam-stock-jumps-as-ldl-c-lowering-drug-scores-again-at-phase-iii Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-validates-chiesi-and-protalixs-dose-variation-for-fabry-disease https://spypharm.com/ema-validates-chiesi-and-protalixs-dose-variation-for-fabry-disease Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/rsv-prophylactic-market-to-reach-62bn-in-8mm-by-2030 https://spypharm.com/rsv-prophylactic-market-to-reach-62bn-in-8mm-by-2030 Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/santheras-dmd-therapy-agamree-approved-for-nhs-use-after-new-price-deal https://spypharm.com/santheras-dmd-therapy-agamree-approved-for-nhs-use-after-new-price-deal Wed, 11 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/lillys-279m-bet-aims-to-boost-uk-life-sciences-sector https://spypharm.com/lillys-279m-bet-aims-to-boost-uk-life-sciences-sector Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/dr-myles-greenberg-becomes-president-and-ceo-of-incarda-therapeutics https://spypharm.com/dr-myles-greenberg-becomes-president-and-ceo-of-incarda-therapeutics Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/ash-2024-jjs-tecvayli-shows-promise-in-transplant-eligible-ndmm-patient https://spypharm.com/ash-2024-jjs-tecvayli-shows-promise-in-transplant-eligible-ndmm-patient Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/ash-2024-regenerons-ordspono-faces-challenges-but-positive-results-signal-hope https://spypharm.com/ash-2024-regenerons-ordspono-faces-challenges-but-positive-results-signal-hope Wed, 11 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/priority-fda-review-given-to-astrazenecas-imfinzi-sbla-for-mibc https://spypharm.com/priority-fda-review-given-to-astrazenecas-imfinzi-sbla-for-mibc Mon, 09 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/fda-rmat-status-for-affimed-and-artivas-lymphoma-combo-therapy https://spypharm.com/fda-rmat-status-for-affimed-and-artivas-lymphoma-combo-therapy Mon, 09 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/dewpoint-therapeutics-and-mitsubishi-tanabe-link-on-als-treatment https://spypharm.com/dewpoint-therapeutics-and-mitsubishi-tanabe-link-on-als-treatment Sat, 07 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/leo-pharmas-eczema-cream-gains-mhra-marketing-authorisation https://spypharm.com/leo-pharmas-eczema-cream-gains-mhra-marketing-authorisation Sat, 07 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/merus-bizengri-granted-fda-accelerated-approval-to-treat-nrg1-cancers https://spypharm.com/merus-bizengri-granted-fda-accelerated-approval-to-treat-nrg1-cancers Sat, 07 Dec 2024 06:00:09 -0500 spectro https://spypharm.com/fda-shares-new-draft-guidance-for-accelerated-approval https://spypharm.com/fda-shares-new-draft-guidance-for-accelerated-approval Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/new-study-finds-obesity-costs-us-industry-347bn-a-year https://spypharm.com/new-study-finds-obesity-costs-us-industry-347bn-a-year Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/eli-lilly-to-invest-3bn-in-wisconsin-facility-expansion https://spypharm.com/eli-lilly-to-invest-3bn-in-wisconsin-facility-expansion Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/centenarians-unlocking-the-secrets-of-living-to-100 https://spypharm.com/centenarians-unlocking-the-secrets-of-living-to-100 Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/muna-gsk-alliance-to-fast-track-alzheimers-disease-treatments https://spypharm.com/muna-gsk-alliance-to-fast-track-alzheimers-disease-treatments Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/fda-armat-status-for-affimed-and-artivas-lymphoma-combo-therapy https://spypharm.com/fda-armat-status-for-affimed-and-artivas-lymphoma-combo-therapy Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/cell-and-gene-therapy-companies-must-demonstrate-strong-value-proposition-for-investment https://spypharm.com/cell-and-gene-therapy-companies-must-demonstrate-strong-value-proposition-for-investment Sat, 07 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/lundbeck-acquires-all-outstanding-shares-of-longboard-pharma https://spypharm.com/lundbeck-acquires-all-outstanding-shares-of-longboard-pharma Thu, 05 Dec 2024 06:00:19 -0500 spectro https://spypharm.com/fda-approves-astrazenecas-imfinzi-to-treat-ls-sclc https://spypharm.com/fda-approves-astrazenecas-imfinzi-to-treat-ls-sclc Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/ceo-of-unitedhealthcare-brian-thompson-shot-dead-in-new-york-city https://spypharm.com/ceo-of-unitedhealthcare-brian-thompson-shot-dead-in-new-york-city Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/lillys-zepbound-wins-the-weight-loss-duel-with-novos-wegovy https://spypharm.com/lillys-zepbound-wins-the-weight-loss-duel-with-novos-wegovy Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/ipsen-and-biomunex-enter-agreement-for-cancer-therapy https://spypharm.com/ipsen-and-biomunex-enter-agreement-for-cancer-therapy Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/takeda-licensed-for-anaemia-therapy-by-keros-therapeutics https://spypharm.com/takeda-licensed-for-anaemia-therapy-by-keros-therapeutics Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/trump-20-could-see-a-rise-in-biopharmaceutical-ma-deals https://spypharm.com/trump-20-could-see-a-rise-in-biopharmaceutical-ma-deals Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/from-cobenfy-to-emraclidine-the-muscarinic-path-to-safer-antipsychotics https://spypharm.com/from-cobenfy-to-emraclidine-the-muscarinic-path-to-safer-antipsychotics Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/maze-therapeutics-raises-115m-to-advance-kidney-disease-candidates https://spypharm.com/maze-therapeutics-raises-115m-to-advance-kidney-disease-candidates Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/all-in-one-milling-platforms-how-to-reduce-your-machinery-footprint https://spypharm.com/all-in-one-milling-platforms-how-to-reduce-your-machinery-footprint Thu, 05 Dec 2024 06:00:18 -0500 spectro https://spypharm.com/cbc-acquires-ucbs-neurology-and-allergy-business-in-china https://spypharm.com/cbc-acquires-ucbs-neurology-and-allergy-business-in-china Tue, 03 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/uq-secures-funds-for-development-of-skin-cancer-prevention-cream https://spypharm.com/uq-secures-funds-for-development-of-skin-cancer-prevention-cream Tue, 03 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/prep-therapies-offer-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass https://spypharm.com/prep-therapies-offer-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass Tue, 03 Dec 2024 06:00:11 -0500 spectro https://spypharm.com/novartis-and-ptc-therapeutics-link-to-develop-huntingtons-therapy https://spypharm.com/novartis-and-ptc-therapeutics-link-to-develop-huntingtons-therapy Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/fate-therapeutics-makes-bob-valamehr-president-and-ceo https://spypharm.com/fate-therapeutics-makes-bob-valamehr-president-and-ceo Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/jjs-sblas-seek-fda-approval-of-tremfya-for-paediatric-conditions https://spypharm.com/jjs-sblas-seek-fda-approval-of-tremfya-for-paediatric-conditions Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/faron-pharma-secures-uk-innovation-passport-for-blood-cancer-immunotherapy https://spypharm.com/faron-pharma-secures-uk-innovation-passport-for-blood-cancer-immunotherapy Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/chmp-recommends-oral-peanut-allergy-immunotherapy-treatment-for-toddlers https://spypharm.com/chmp-recommends-oral-peanut-allergy-immunotherapy-treatment-for-toddlers Tue, 03 Dec 2024 06:00:10 -0500 spectro https://spypharm.com/ema-launches-esmp-for-better-management-of-drug-shortages-in-eu https://spypharm.com/ema-launches-esmp-for-better-management-of-drug-shortages-in-eu Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/university-of-birmingham-identifies-target-to-reduce-gvhd-risk https://spypharm.com/university-of-birmingham-identifies-target-to-reduce-gvhd-risk Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/uk-government-to-launch-first-ever-mens-health-strategy https://spypharm.com/uk-government-to-launch-first-ever-mens-health-strategy Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/prep-therapies-utter-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass https://spypharm.com/prep-therapies-utter-new-hope-in-hiv-preventive-landscape-as-vaccine-failures-amass Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/uk-reports-near-eradication-of-meningitis-c-amid-declining-vaccine-uptake https://spypharm.com/uk-reports-near-eradication-of-meningitis-c-amid-declining-vaccine-uptake Sun, 01 Dec 2024 06:00:08 -0500 spectro https://spypharm.com/kronos-bio-announces-interim-ceo-and-workforce-cuts-of-83 https://spypharm.com/kronos-bio-announces-interim-ceo-and-workforce-cuts-of-83 Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/trump-agency-nominations-show-pharma-industry-as-divided-as-us https://spypharm.com/trump-agency-nominations-show-pharma-industry-as-divided-as-us Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/health-canada-approves-novo-nordisks-wegovy-to-cut-heart-attacks https://spypharm.com/health-canada-approves-novo-nordisks-wegovy-to-cut-heart-attacks Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/combatting-infectious-disease-challenges-and-opportunities-for-pharma-in-the-green-transition https://spypharm.com/combatting-infectious-disease-challenges-and-opportunities-for-pharma-in-the-green-transition Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/cervomeds-stock-rises-as-fda-grants-orphan-drug-status-to-dementia-drug https://spypharm.com/cervomeds-stock-rises-as-fda-grants-orphan-drug-status-to-dementia-drug Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/wait-for-galactosemia-therapy-goes-on-after-fda-shuns-applied-therapeutics-govorestat https://spypharm.com/wait-for-galactosemia-therapy-goes-on-after-fda-shuns-applied-therapeutics-govorestat Fri, 29 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/allink-biotherapeutics-secures-funding-to-advance-adc-pipeline https://spypharm.com/allink-biotherapeutics-secures-funding-to-advance-adc-pipeline Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/formosa-and-medvisis-agree-on-post-operative-eye-pain-therapy https://spypharm.com/formosa-and-medvisis-agree-on-post-operative-eye-pain-therapy Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/trump-20-spells-global-change-in-pharmaceutical-regulation-funding-and-investment https://spypharm.com/trump-20-spells-global-change-in-pharmaceutical-regulation-funding-and-investment Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/advanz-pharmas-liver-disease-drug-pulled-from-european-market-after-court-hearing https://spypharm.com/advanz-pharmas-liver-disease-drug-pulled-from-european-market-after-court-hearing Fri, 29 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/eton-acquires-us-rights-to-neonatal-diabetes-treatment-from-ammtek https://spypharm.com/eton-acquires-us-rights-to-neonatal-diabetes-treatment-from-ammtek Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/roche-to-acquire-poseida-therapeutics-for-15bn https://spypharm.com/roche-to-acquire-poseida-therapeutics-for-15bn Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/shorla-oncologys-imkeldi-approved-by-fda-for-leukaemia-cancers https://spypharm.com/shorla-oncologys-imkeldi-approved-by-fda-for-leukaemia-cancers Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/adcendo-raises-135m-as-adc-funding-frenzy-continues https://spypharm.com/adcendo-raises-135m-as-adc-funding-frenzy-continues Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/nhs-rolls-out-monoclonal-antibody-treatment-for-rare-bone-disease https://spypharm.com/nhs-rolls-out-monoclonal-antibody-treatment-for-rare-bone-disease Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/roches-tiragolumab-flops-in-another-phase-iii-lung-cancer-trial https://spypharm.com/roches-tiragolumab-flops-in-another-phase-iii-lung-cancer-trial Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/gilead-adds-investigational-hiv-vaccine-to-its-portfolio-from-spanish-biotech https://spypharm.com/gilead-adds-investigational-hiv-vaccine-to-its-portfolio-from-spanish-biotech Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-pci-pharma-services https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-pci-pharma-services Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/sustainability-in-biopharma-collaboration-and-technology-light-the-way-forward https://spypharm.com/sustainability-in-biopharma-collaboration-and-technology-light-the-way-forward Wed, 27 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/arrowhead-and-sarepta-link-for-rare-genetic-disease-treatments https://spypharm.com/arrowhead-and-sarepta-link-for-rare-genetic-disease-treatments Wed, 27 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/fda-approves-bridgebios-attruby-for-attr-cm-treatment https://spypharm.com/fda-approves-bridgebios-attruby-for-attr-cm-treatment Mon, 25 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/zai-lab-and-pfizer-to-commercialise-xacduro-in-china https://spypharm.com/zai-lab-and-pfizer-to-commercialise-xacduro-in-china Sat, 23 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/novartis-acquires-kate-therapeutics-to-advance-gene-therapies https://spypharm.com/novartis-acquires-kate-therapeutics-to-advance-gene-therapies Sat, 23 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector https://spypharm.com/amneal-files-again-for-fda-approval-of-first-dihydroergotamine-autoinjector Sat, 23 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/magazine-pharmas-green-shift-with-dry-powder-inhalers https://spypharm.com/magazine-pharmas-green-shift-with-dry-powder-inhalers Sat, 23 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/health-canada-issues-noc-to-jjs-carvykti-for-multiple-myeloma https://spypharm.com/health-canada-issues-noc-to-jjs-carvykti-for-multiple-myeloma Sat, 23 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/europes-tcr-immunotherapy-licensing-deals-surge-123-above-us-in-2024 https://spypharm.com/europes-tcr-immunotherapy-licensing-deals-surge-123-above-us-in-2024 Sat, 23 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/uk-point-of-care-production-of-cell-therapies-could-arrive-in-2025 https://spypharm.com/uk-point-of-care-production-of-cell-therapies-could-arrive-in-2025 Sat, 23 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/jj-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis https://spypharm.com/jj-eyes-fda-approval-for-injection-based-tremfya-in-ulcerative-colitis Sat, 23 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/no-magic-wand-for-novo-nordisk-as-cagrisema-pen-supply-rumours-swirl https://spypharm.com/no-magic-wand-for-novo-nordisk-as-cagrisema-pen-supply-rumours-swirl Sat, 23 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/enveda-raises-130m-to-advance-ai-driven-plant-based-drug-development https://spypharm.com/enveda-raises-130m-to-advance-ai-driven-plant-based-drug-development Sat, 23 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/pharmanovia-signs-license-agreement-for-lindis-biotechs-catumaxomab https://spypharm.com/pharmanovia-signs-license-agreement-for-lindis-biotechs-catumaxomab Thu, 21 Nov 2024 06:00:13 -0500 spectro https://spypharm.com/wes-streeting-says-patients-should-view-data-sharing-the-same-as-taxes https://spypharm.com/wes-streeting-says-patients-should-view-data-sharing-the-same-as-taxes Thu, 21 Nov 2024 06:00:13 -0500 spectro https://spypharm.com/km-biologics-mpox-vaccine-approved-for-emergency-use-by-who https://spypharm.com/km-biologics-mpox-vaccine-approved-for-emergency-use-by-who Thu, 21 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/tris-pharma-receives-ex-us-approvals-for-adhd-treatments https://spypharm.com/tris-pharma-receives-ex-us-approvals-for-adhd-treatments Thu, 21 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/parkinsons-disease-cases-to-reach-315-million-in-7mm-by-2033 https://spypharm.com/parkinsons-disease-cases-to-reach-315-million-in-7mm-by-2033 Thu, 21 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/veeva-commercial-summit-increased-investment-in-medical-affairs-by-pharma-companies https://spypharm.com/veeva-commercial-summit-increased-investment-in-medical-affairs-by-pharma-companies Thu, 21 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/ec-marketing-authorisation-granted-to-pfizers-hympavzi-for-haemophilia https://spypharm.com/ec-marketing-authorisation-granted-to-pfizers-hympavzi-for-haemophilia Thu, 21 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/leading-sales-enablement-prospecting-and-automation-providers-and-technology-solutions-for-the-pharmaceutical-industry https://spypharm.com/leading-sales-enablement-prospecting-and-automation-providers-and-technology-solutions-for-the-pharmaceutical-industry Thu, 21 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/uk-life-science-startups-have-trouble-scaling-up-says-lord-vallance https://spypharm.com/uk-life-science-startups-have-trouble-scaling-up-says-lord-vallance Thu, 21 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/kura-oncology-partners-kyowa-kirin-to-advance-aml-treatment https://spypharm.com/kura-oncology-partners-kyowa-kirin-to-advance-aml-treatment Thu, 21 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/emas-chmp-to-approve-bms-opdivo-for-colorectal-cancer https://spypharm.com/emas-chmp-to-approve-bms-opdivo-for-colorectal-cancer Tue, 19 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults https://spypharm.com/aha-2024-plozasiran-demonstrates-promising-phase-iii-results-in-fcs-adults Tue, 19 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/aha-2024-lerodalcibep-provides-promising-results-in-open-label-extension-trial-liberate-ole https://spypharm.com/aha-2024-lerodalcibep-provides-promising-results-in-open-label-extension-trial-liberate-ole Tue, 19 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/chmp-recommends-astrazenecas-tagrisso-for-eu-approval-for-nsclc https://spypharm.com/chmp-recommends-astrazenecas-tagrisso-for-eu-approval-for-nsclc Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/sandozs-afqlir-gains-ec-marketing-authorisation-for-retinal-diseases https://spypharm.com/sandozs-afqlir-gains-ec-marketing-authorisation-for-retinal-diseases Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/fda-approves-syndaxs-revuforj-to-treat-leukaemia https://spypharm.com/fda-approves-syndaxs-revuforj-to-treat-leukaemia Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/aha-2024-tirzepatide-improves-outcomes-for-major-heart-failure-with-hfpef-and-obesity-in-summit https://spypharm.com/aha-2024-tirzepatide-improves-outcomes-for-major-heart-failure-with-hfpef-and-obesity-in-summit Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/astrazeneca-picks-first-treg-cell-therapy-from-quell-therapeutics-partnership https://spypharm.com/astrazeneca-picks-first-treg-cell-therapy-from-quell-therapeutics-partnership Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/intellias-gene-editing-therapy-shows-early-potential-in-rare-heart-condition https://spypharm.com/intellias-gene-editing-therapy-shows-early-potential-in-rare-heart-condition Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/abbvies-elahere-wins-european-approval-for-certain-ovarian-cancers https://spypharm.com/abbvies-elahere-wins-european-approval-for-certain-ovarian-cancers Tue, 19 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/bavarian-nordic-shares-sink-by-12-after-mpox-sales-slump-in-q3 https://spypharm.com/bavarian-nordic-shares-sink-by-12-after-mpox-sales-slump-in-q3 Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/fda-reviews-sanofi-and-regenerons-dupixent-label-expansion-for-urticaria https://spypharm.com/fda-reviews-sanofi-and-regenerons-dupixent-label-expansion-for-urticaria Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/ac-immunes-stock-jumps-after-parkinsons-therapy-shows-signs-of-benefit https://spypharm.com/ac-immunes-stock-jumps-after-parkinsons-therapy-shows-signs-of-benefit Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment https://spypharm.com/fda-approves-azurity-pharmaceuticals-danziten-for-cml-treatment Sun, 17 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/metsera-raises-215m-in-series-b-round-for-weight-loss-candidates https://spypharm.com/metsera-raises-215m-in-series-b-round-for-weight-loss-candidates Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development https://spypharm.com/kronos-mulls-strategic-alternatives-after-axing-cancer-drug-development Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints https://spypharm.com/adaptimmune-nears-second-sarcoma-approval-as-phase-ii-trial-hits-endpoints Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/fda-grants-accelerated-approval-for-ptcs-aadc-deficiency-gene-therapy https://spypharm.com/fda-grants-accelerated-approval-for-ptcs-aadc-deficiency-gene-therapy Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/huaweis-top-10-construction-principles-for-intelligent-computing-centre-facilities https://spypharm.com/huaweis-top-10-construction-principles-for-intelligent-computing-centre-facilities Fri, 15 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/msd-secures-worldwide-license-for-lanovas-lm-299 https://spypharm.com/msd-secures-worldwide-license-for-lanovas-lm-299 Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/emas-chmp-recommends-sanofis-sarclisa-approval-for-multiple-myeloma https://spypharm.com/emas-chmp-recommends-sanofis-sarclisa-approval-for-multiple-myeloma Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/trump-picks-vaccine-sceptic-rfk-jr-to-lead-hhs-in-new-administration https://spypharm.com/trump-picks-vaccine-sceptic-rfk-jr-to-lead-hhs-in-new-administration Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/ema-committee-rethinks-stance-and-recommends-leqembi-for-alzheimers-disease https://spypharm.com/ema-committee-rethinks-stance-and-recommends-leqembi-for-alzheimers-disease Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/leading-account-and-intent-based-sales-and-marketing-providers-and-technology-solutions-for-the-pharmaceutical-industry https://spypharm.com/leading-account-and-intent-based-sales-and-marketing-providers-and-technology-solutions-for-the-pharmaceutical-industry Fri, 15 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/nhs-launches-game-changer-and-lifesaving-anti-smoking-pill https://spypharm.com/nhs-launches-game-changer-and-lifesaving-anti-smoking-pill Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/idweek-2024-strategic-approaches-and-challenges-in-mpox-vaccination https://spypharm.com/idweek-2024-strategic-approaches-and-challenges-in-mpox-vaccination Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-bostongene https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-bostongene Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/pfizer-considers-divestiture-of-hospital-drugs-business https://spypharm.com/pfizer-considers-divestiture-of-hospital-drugs-business Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine https://spypharm.com/fda-clears-novavax-to-resume-trials-of-covid-19-and-flu-combo-vaccine Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/are-dry-powder-inhalers-the-key-to-sustainable-respiratory-care https://spypharm.com/are-dry-powder-inhalers-the-key-to-sustainable-respiratory-care Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/dmts-are-major-clinical-research-focus-for-parkinsons-disease-analysis-shows https://spypharm.com/dmts-are-major-clinical-research-focus-for-parkinsons-disease-analysis-shows Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/uppsala-and-kth-royal-develop-antibody-for-potential-cancer-treatment https://spypharm.com/uppsala-and-kth-royal-develop-antibody-for-potential-cancer-treatment Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/zai-lab-and-argenx-announce-nmpa-approval-for-sbla-for-vyvgart-hytrulo https://spypharm.com/zai-lab-and-argenx-announce-nmpa-approval-for-sbla-for-vyvgart-hytrulo Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/fda-grants-breakthrough-status-to-jjs-nipocalimab-for-sjd-treatment https://spypharm.com/fda-grants-breakthrough-status-to-jjs-nipocalimab-for-sjd-treatment Wed, 13 Nov 2024 06:00:11 -0500 spectro https://spypharm.com/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib https://spypharm.com/dizal-seeks-fda-approval-for-nsclc-treatment-sunvozertinib Mon, 11 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/investment-surges-hurdles-and-emerging-innovations-in-neuroscience https://spypharm.com/investment-surges-hurdles-and-emerging-innovations-in-neuroscience Mon, 11 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/santen-arctic-vision-sign-deal-for-arvn001-to-treat-ume https://spypharm.com/santen-arctic-vision-sign-deal-for-arvn001-to-treat-ume Sat, 09 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/private-equity-deals-in-pharmaceutical-in-canada-remained-flat-in-q3-2024 https://spypharm.com/private-equity-deals-in-pharmaceutical-in-canada-remained-flat-in-q3-2024 Sat, 09 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/ultra-processed-food-is-causing-a-boom-for-obesity-drug-ozempic https://spypharm.com/ultra-processed-food-is-causing-a-boom-for-obesity-drug-ozempic Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/eisai-lowers-leqembi-revenue-forecast-after-rocky-entry-to-market https://spypharm.com/eisai-lowers-leqembi-revenue-forecast-after-rocky-entry-to-market Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/the-fundamentals-of-developing-parenteral-drug-products https://spypharm.com/the-fundamentals-of-developing-parenteral-drug-products Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets https://spypharm.com/aurinia-slashes-workforce-by-45-to-focus-on-lupus-and-autoimmune-assets Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine https://spypharm.com/lakeshore-commences-bla-submission-to-drap-for-rabies-vaccine Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/astrazeneca-and-amgens-tezspire-succeeds-in-phase-iii-nasal-polyps-trial https://spypharm.com/astrazeneca-and-amgens-tezspire-succeeds-in-phase-iii-nasal-polyps-trial Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/mustang-bios-mb-108-receives-fda-orphan-drug-status-for-glioma-treatment https://spypharm.com/mustang-bios-mb-108-receives-fda-orphan-drug-status-for-glioma-treatment Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/sonnet-biotherapeutics-secures-us-patent-covering-two-drug-candidates https://spypharm.com/sonnet-biotherapeutics-secures-us-patent-covering-two-drug-candidates Sat, 09 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/zentiva-voices-uwwtd-concerns-as-eu-grants-approval https://spypharm.com/zentiva-voices-uwwtd-concerns-as-eu-grants-approval Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/strong-wegovy-revenue-growth-for-novo-nordisk-but-shares-dip https://spypharm.com/strong-wegovy-revenue-growth-for-novo-nordisk-but-shares-dip Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/tevogen-bio-partners-microsoft-for-hpv-treatment https://spypharm.com/tevogen-bio-partners-microsoft-for-hpv-treatment Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/trump-triumphs-but-impact-on-healthcare-industry-remains-unclear https://spypharm.com/trump-triumphs-but-impact-on-healthcare-industry-remains-unclear Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/nxera-pharma-and-antiverse-to-design-antibodies-targeting-gpcrs https://spypharm.com/nxera-pharma-and-antiverse-to-design-antibodies-targeting-gpcrs Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/deepmind-nobel-prize-winner-says-ai-will-have-electricity-type-of-impact https://spypharm.com/deepmind-nobel-prize-winner-says-ai-will-have-electricity-type-of-impact Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win https://spypharm.com/intra-cellular-bolsters-caplyta-data-with-another-phase-iii-win Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/top-20-biopharmas-market-cap-rises-2-in-q3-2024-amid-flurry-of-drug-approvals https://spypharm.com/top-20-biopharmas-market-cap-rises-2-in-q3-2024-amid-flurry-of-drug-approvals Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/gsk-ceo-addresses-declining-trust-in-vaccines-following-trump-re-election https://spypharm.com/gsk-ceo-addresses-declining-trust-in-vaccines-following-trump-re-election Thu, 07 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/ema-approves-sanofiregenerons-dupixent-for-young-eoe-patients https://spypharm.com/ema-approves-sanofiregenerons-dupixent-for-young-eoe-patients Thu, 07 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/prokarium-bolsters-ip-portfolio-with-two-new-us-patents https://spypharm.com/prokarium-bolsters-ip-portfolio-with-two-new-us-patents Tue, 05 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/fda-grants-fast-track-status-to-feliqss-flq-101-to-prevent-rop https://spypharm.com/fda-grants-fast-track-status-to-feliqss-flq-101-to-prevent-rop Tue, 05 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/us-election-in-close-race-tiny-senate-majority-not-president-will-hold-power https://spypharm.com/us-election-in-close-race-tiny-senate-majority-not-president-will-hold-power Tue, 05 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/northwestern-and-case-western-reserve-universities-develop-huntingtons-therapy https://spypharm.com/northwestern-and-case-western-reserve-universities-develop-huntingtons-therapy Tue, 05 Nov 2024 06:00:09 -0500 spectro https://spypharm.com/syndax-agrees-funding-with-royalty-pharma-for-niktimvo-us-sales https://spypharm.com/syndax-agrees-funding-with-royalty-pharma-for-niktimvo-us-sales Tue, 05 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/injectables-manufacturing-ushers-in-a-new-era-of-accessibility https://spypharm.com/injectables-manufacturing-ushers-in-a-new-era-of-accessibility Tue, 05 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/disc-teases-potential-nda-for-rare-skin-disorder-drug https://spypharm.com/disc-teases-potential-nda-for-rare-skin-disorder-drug Tue, 05 Nov 2024 06:00:08 -0500 spectro https://spypharm.com/ec-fines-teva-502m-over-multiple-sclerosis-treatment-copaxone-practices https://spypharm.com/ec-fines-teva-502m-over-multiple-sclerosis-treatment-copaxone-practices Sun, 03 Nov 2024 06:00:12 -0500 spectro https://spypharm.com/us-court-upholds-avadels-narcolepsy-drug-approval-amid-exclusivity-battle https://spypharm.com/us-court-upholds-avadels-narcolepsy-drug-approval-amid-exclusivity-battle Sun, 03 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/abbvie-and-evolveimmune-therapeutics-sign-oncology-collaboration https://spypharm.com/abbvie-and-evolveimmune-therapeutics-sign-oncology-collaboration Sun, 03 Nov 2024 06:00:10 -0500 spectro https://spypharm.com/nccn-visits-vietnam-in-continued-cancer-care-collaboration https://spypharm.com/nccn-visits-vietnam-in-continued-cancer-care-collaboration Sun, 03 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/how-hybrid-models-and-tech-are-shaping-the-future-of-clinical-research https://spypharm.com/how-hybrid-models-and-tech-are-shaping-the-future-of-clinical-research Sun, 03 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/lexicon-stock-tumbles-after-fda-adcom-votes-against-zynquista-again https://spypharm.com/lexicon-stock-tumbles-after-fda-adcom-votes-against-zynquista-again Sun, 03 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/verastem-oncology-submits-nda-for-ovarian-cancer-treatment https://spypharm.com/verastem-oncology-submits-nda-for-ovarian-cancer-treatment Sun, 03 Nov 2024 06:00:07 -0500 spectro https://spypharm.com/bladder-cancer-diagnoses-to-top-300000-in-major-markets-by-2033 https://spypharm.com/bladder-cancer-diagnoses-to-top-300000-in-major-markets-by-2033 Fri, 01 Nov 2024 04:00:08 -0400 spectro https://spypharm.com/biogen-and-neomorph-enter-molecular-glue-degrader-deal https://spypharm.com/biogen-and-neomorph-enter-molecular-glue-degrader-deal Fri, 01 Nov 2024 04:00:08 -0400 spectro https://spypharm.com/will-the-tide-turn-for-the-wave-of-pharma-layoffs https://spypharm.com/will-the-tide-turn-for-the-wave-of-pharma-layoffs Fri, 01 Nov 2024 04:00:08 -0400 spectro https://spypharm.com/pfizer-boasts-over-30-increase-in-q3-revenues-against-previous-year https://spypharm.com/pfizer-boasts-over-30-increase-in-q3-revenues-against-previous-year Fri, 01 Nov 2024 04:00:08 -0400 spectro https://spypharm.com/for-pharma-companies-the-possibilities-of-green-chemistry-are-huge https://spypharm.com/for-pharma-companies-the-possibilities-of-green-chemistry-are-huge Fri, 01 Nov 2024 04:00:08 -0400 spectro https://spypharm.com/roche-to-leverage-dyno-therapeutics-tech-for-novel-gene-therapies-in-neuro-disorders https://spypharm.com/roche-to-leverage-dyno-therapeutics-tech-for-novel-gene-therapies-in-neuro-disorders Fri, 01 Nov 2024 04:00:08 -0400 spectro https://spypharm.com/reeves-2024-budget-promises-life-sciences-investment https://spypharm.com/reeves-2024-budget-promises-life-sciences-investment Fri, 01 Nov 2024 04:00:07 -0400 spectro https://spypharm.com/matinas-biopharma-mulls-wind-down-as-antifungal-therapy-deal-falls-through https://spypharm.com/matinas-biopharma-mulls-wind-down-as-antifungal-therapy-deal-falls-through Fri, 01 Nov 2024 04:00:07 -0400 spectro https://spypharm.com/amgen-earns-higher-revenues-in-q3-2024-puts-rare-diseases-in-the-spotlight https://spypharm.com/amgen-earns-higher-revenues-in-q3-2024-puts-rare-diseases-in-the-spotlight Fri, 01 Nov 2024 04:00:07 -0400 spectro https://spypharm.com/psoriasis-biosimilars-and-pricing-changes-herald-treatment-paradigm-disruptions https://spypharm.com/psoriasis-biosimilars-and-pricing-changes-herald-treatment-paradigm-disruptions Fri, 01 Nov 2024 04:00:07 -0400 spectro https://spypharm.com/abbvie-signs-agreement-to-acquire-aliada-for-14bn https://spypharm.com/abbvie-signs-agreement-to-acquire-aliada-for-14bn Wed, 30 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/what-is-the-pharmacy-of-the-future https://spypharm.com/what-is-the-pharmacy-of-the-future Wed, 30 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/upfs-fuelling-alarming-rise-of-chronic-diseases-in-india https://spypharm.com/upfs-fuelling-alarming-rise-of-chronic-diseases-in-india Wed, 30 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/transforming-pharmaceutical-rd-the-impact-of-digital-technologies-on-drug-discovery-and-development https://spypharm.com/transforming-pharmaceutical-rd-the-impact-of-digital-technologies-on-drug-discovery-and-development Wed, 30 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/dermavant-acquisitionexpands-organons-dermatology-portfolio https://spypharm.com/dermavant-acquisitionexpands-organons-dermatology-portfolio Wed, 30 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/ec-approves-astrazenecas-fasenra-for-egpa-treatment https://spypharm.com/ec-approves-astrazenecas-fasenra-for-egpa-treatment Wed, 30 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/arrivo-targets-major-depressive-disorder-in-females-after-early-efficacy-data https://spypharm.com/arrivo-targets-major-depressive-disorder-in-females-after-early-efficacy-data Wed, 30 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial https://spypharm.com/bavarian-eyes-mpox-vaccine-label-expansion-to-include-toddlers-kickstarts-phase-ii-trial Wed, 30 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/us-border-protection-warns-pharma-of-risks-with-incorrect-biologic-importation https://spypharm.com/us-border-protection-warns-pharma-of-risks-with-incorrect-biologic-importation Wed, 30 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/south-korean-pricing-reform-suggests-more-flexible-drug-reimbursement-negotiations https://spypharm.com/south-korean-pricing-reform-suggests-more-flexible-drug-reimbursement-negotiations Wed, 30 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/takeda-and-bmc-partner-to-decarbonise-us-healthcare-sector https://spypharm.com/takeda-and-bmc-partner-to-decarbonise-us-healthcare-sector Sat, 26 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/abbvie-and-richter-partner-for-neuropsychiatric-treatments https://spypharm.com/abbvie-and-richter-partner-for-neuropsychiatric-treatments Sat, 26 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/us-cdc-adcom-recommends-lowering-the-age-for-pneumococcal-vaccines https://spypharm.com/us-cdc-adcom-recommends-lowering-the-age-for-pneumococcal-vaccines Sat, 26 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/gsk-pumps-up-to-800m-for-us-manufacturing-site-upgrade https://spypharm.com/gsk-pumps-up-to-800m-for-us-manufacturing-site-upgrade Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/dyno-and-roche-collaborate-on-neurological-gene-therapies https://spypharm.com/dyno-and-roche-collaborate-on-neurological-gene-therapies Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/pharma-companies-must-adapt-to-keep-pace-with-ai-developments-say-experts https://spypharm.com/pharma-companies-must-adapt-to-keep-pace-with-ai-developments-say-experts Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/af-stroke-patients-could-benefit-from-earlier-anticoagulant-administration https://spypharm.com/af-stroke-patients-could-benefit-from-earlier-anticoagulant-administration Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/leos-adbry-demonstrates-long-term-efficacy-in-atopic-dermatitis https://spypharm.com/leos-adbry-demonstrates-long-term-efficacy-in-atopic-dermatitis Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/lyell-goes-all-in-on-car-t-therapies-buys-immpact-bio-and-trims-pipeline https://spypharm.com/lyell-goes-all-in-on-car-t-therapies-buys-immpact-bio-and-trims-pipeline Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/sanofi-backed-agomab-raises-89m-to-advance-fibrotic-disease-treatments https://spypharm.com/sanofi-backed-agomab-raises-89m-to-advance-fibrotic-disease-treatments Sat, 26 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/be-bio-raises-82m-to-advance-haemophilia-b-gene-therapy-to-phase-iii-trial https://spypharm.com/be-bio-raises-82m-to-advance-haemophilia-b-gene-therapy-to-phase-iii-trial Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/ocuphire-and-opus-genetics-merge-to-develop-ird-gene-therapy https://spypharm.com/ocuphire-and-opus-genetics-merge-to-develop-ird-gene-therapy Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/aao-2024-nma-reveals-vabysmos-superior-cst-improvement-over-eylea-hd https://spypharm.com/aao-2024-nma-reveals-vabysmos-superior-cst-improvement-over-eylea-hd Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/health-canada-approves-serviers-voranigo-for-idh-mutant-glioma https://spypharm.com/health-canada-approves-serviers-voranigo-for-idh-mutant-glioma Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/a-slow-start-for-self-amplifying-mrna-vaccines https://spypharm.com/a-slow-start-for-self-amplifying-mrna-vaccines Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/gilead-and-msd-to-advance-once-weekly-hiv-treatment-to-phase-iii https://spypharm.com/gilead-and-msd-to-advance-once-weekly-hiv-treatment-to-phase-iii Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/jjs-darzalex-combination-gains-expanded-label-for-multiple-myeloma-in-europe https://spypharm.com/jjs-darzalex-combination-gains-expanded-label-for-multiple-myeloma-in-europe Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/fda-expands-pfizers-rsv-vaccine-label-to-include-all-high-risk-adults https://spypharm.com/fda-expands-pfizers-rsv-vaccine-label-to-include-all-high-risk-adults Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/fda-approves-alvotech-and-tevas-selarsdi-for-new-indications https://spypharm.com/fda-approves-alvotech-and-tevas-selarsdi-for-new-indications Thu, 24 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/lillys-kisunla-does-not-demonstrate-good-value-for-uks-nhs https://spypharm.com/lillys-kisunla-does-not-demonstrate-good-value-for-uks-nhs Thu, 24 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/immunoprecise-touts-potential-of-rabbit-monoclonal-antibodies-in-oncology https://spypharm.com/immunoprecise-touts-potential-of-rabbit-monoclonal-antibodies-in-oncology Tue, 22 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fibrobiologics-and-charles-river-link-for-chronic-disease-therapies-manufacture https://spypharm.com/fibrobiologics-and-charles-river-link-for-chronic-disease-therapies-manufacture Tue, 22 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4s-nsclc-therapy https://spypharm.com/fda-clamps-partial-hold-on-phase-iii-trial-of-biontech-oncoc4s-nsclc-therapy Tue, 22 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fda-approves-astellas-vyloy-for-gastric-cancer-treatment https://spypharm.com/fda-approves-astellas-vyloy-for-gastric-cancer-treatment Tue, 22 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/cambridge-university-and-gsk-sign-immunology-rd-collaboration https://spypharm.com/cambridge-university-and-gsk-sign-immunology-rd-collaboration Tue, 22 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/thermo-fishers-oncomine-gains-fda-approval-as-brain-tumor-diagnostic https://spypharm.com/thermo-fishers-oncomine-gains-fda-approval-as-brain-tumor-diagnostic Tue, 22 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/aao-2024-nanoscope-therapeutics-mco-010-restores-vision-in-rp-patients https://spypharm.com/aao-2024-nanoscope-therapeutics-mco-010-restores-vision-in-rp-patients Tue, 22 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/sanofis-17bn-sale-of-opella-to-us-investors-advances-following-government-deal https://spypharm.com/sanofis-17bn-sale-of-opella-to-us-investors-advances-following-government-deal Tue, 22 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/health-canada-approves-arcutis-zoryve-foam-for-seborrheic-dermatitis https://spypharm.com/health-canada-approves-arcutis-zoryve-foam-for-seborrheic-dermatitis Tue, 22 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/seaport-raises-225m-to-advance-portfolio-of-neuropsychiatric-prodrugs https://spypharm.com/seaport-raises-225m-to-advance-portfolio-of-neuropsychiatric-prodrugs Tue, 22 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/sanofi-and-orano-med-link-for-radioligand-therapy-development https://spypharm.com/sanofi-and-orano-med-link-for-radioligand-therapy-development Sun, 20 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/opioid-addiction-market-to-reach-24-billion-across-8mm-by-2033 https://spypharm.com/opioid-addiction-market-to-reach-24-billion-across-8mm-by-2033 Sun, 20 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fda-approves-abbvies-vyalev-for-advanced-parkinsons-treatment https://spypharm.com/fda-approves-abbvies-vyalev-for-advanced-parkinsons-treatment Sun, 20 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/theracosbio-and-bamco-to-bring-brenzavvy-to-sub-saharan-africa-for-t2d https://spypharm.com/theracosbio-and-bamco-to-bring-brenzavvy-to-sub-saharan-africa-for-t2d Sun, 20 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/unresolved-clawback-issues-obstruct-greeces-potential-pharmaceutical-framework-agreement https://spypharm.com/unresolved-clawback-issues-obstruct-greeces-potential-pharmaceutical-framework-agreement Sun, 20 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/us-elections-how-healthcare-could-look-under-a-harris-or-trump-administration https://spypharm.com/us-elections-how-healthcare-could-look-under-a-harris-or-trump-administration Sun, 20 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/msd-mulls-202526-launch-for-rsv-vaccine-after-phase-iiiii-win https://spypharm.com/msd-mulls-202526-launch-for-rsv-vaccine-after-phase-iiiii-win Sun, 20 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/mrna-licensing-agreements-surge-800-amid-gsk-lawsuits https://spypharm.com/mrna-licensing-agreements-surge-800-amid-gsk-lawsuits Sun, 20 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/intercepts-liver-disease-drug-ocaliva-faces-fda-approval-delay https://spypharm.com/intercepts-liver-disease-drug-ocaliva-faces-fda-approval-delay Sun, 20 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/avadel-wins-fda-approval-for-narcolepsy-drug-lumryz-in-children https://spypharm.com/avadel-wins-fda-approval-for-narcolepsy-drug-lumryz-in-children Sun, 20 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/radiopharm-and-atomvie-partner-on-radioantibody-development https://spypharm.com/radiopharm-and-atomvie-partner-on-radioantibody-development Fri, 18 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/sage-lays-off-55-of-rd-workforce-and-refocuses-pipeline https://spypharm.com/sage-lays-off-55-of-rd-workforce-and-refocuses-pipeline Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/health-canada-approves-acadias-daybue-for-rett-syndrome https://spypharm.com/health-canada-approves-acadias-daybue-for-rett-syndrome Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/lexicon-partners-viatris-for-global-expansion-of-sotagliflozin https://spypharm.com/lexicon-partners-viatris-for-global-expansion-of-sotagliflozin Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/jj-trims-neuroscience-pipeline-seltorexant-in-alzheimers-disease-dropped https://spypharm.com/jj-trims-neuroscience-pipeline-seltorexant-in-alzheimers-disease-dropped Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/bitbio-defends-european-patent-for-novel-opti-ox-technology https://spypharm.com/bitbio-defends-european-patent-for-novel-opti-ox-technology Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/bavarian-nordics-mpox-vaccine-equally-effective-in-teens-as-adults https://spypharm.com/bavarian-nordics-mpox-vaccine-equally-effective-in-teens-as-adults Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/fresenius-kabi-and-cellular-origins-agree-cgt-manufacture-automation https://spypharm.com/fresenius-kabi-and-cellular-origins-agree-cgt-manufacture-automation Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/glaukos-eyes-fda-approval-for-ocular-therapy-after-phase-iii-win https://spypharm.com/glaukos-eyes-fda-approval-for-ocular-therapy-after-phase-iii-win Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/eli-lilly-will-build-new-way-of-doing-science-in-uk-amid-297m-pledge-to-government https://spypharm.com/eli-lilly-will-build-new-way-of-doing-science-in-uk-amid-297m-pledge-to-government Fri, 18 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/almirall-completes-eu-regulatory-procedure-for-antifungal-jublia https://spypharm.com/almirall-completes-eu-regulatory-procedure-for-antifungal-jublia Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/the-growing-role-of-cdmos-in-the-circular-economy https://spypharm.com/the-growing-role-of-cdmos-in-the-circular-economy Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/parenteral-solutions-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/parenteral-solutions-in-contract-manufacturing-for-the-pharmaceutical-industry Wed, 16 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/hanmi-and-medic-ink-cancer-biomarker-collaboration-deal https://spypharm.com/hanmi-and-medic-ink-cancer-biomarker-collaboration-deal Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/bayer-applies-for-eu-approval-of-menopause-drug-elinzanetant https://spypharm.com/bayer-applies-for-eu-approval-of-menopause-drug-elinzanetant Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/digital-twins-a-new-path-to-personalised-medicine https://spypharm.com/digital-twins-a-new-path-to-personalised-medicine Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-science-of-viscous-drug-product-filling-pumps-pressure-and-process-optimization https://spypharm.com/the-science-of-viscous-drug-product-filling-pumps-pressure-and-process-optimization Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/lilly-touts-omvohs-superiority-over-jjs-stelara-in-crohns https://spypharm.com/lilly-touts-omvohs-superiority-over-jjs-stelara-in-crohns Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/transgenes-stock-drops-after-phase-ii-cancer-jab-trial-misses-primary-endpoint https://spypharm.com/transgenes-stock-drops-after-phase-ii-cancer-jab-trial-misses-primary-endpoint Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/gitex-global-2024-huawei-launches-a-series-of-industrial-digital-and-intelligent-transformation-solutions-and-flagship-products https://spypharm.com/gitex-global-2024-huawei-launches-a-series-of-industrial-digital-and-intelligent-transformation-solutions-and-flagship-products Wed, 16 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing https://spypharm.com/cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing Mon, 14 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/xtalpis-ai-biologics-discovery-platform-licensed-to-janssen-biotech https://spypharm.com/xtalpis-ai-biologics-discovery-platform-licensed-to-janssen-biotech Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/booster-therapeutics-to-develop-proteasome-activator-medicines https://spypharm.com/booster-therapeutics-to-develop-proteasome-activator-medicines Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cphi-europe-targeting-supply-chain-bottlenecks-key-for-cell-and-gene-therapies https://spypharm.com/cphi-europe-targeting-supply-chain-bottlenecks-key-for-cell-and-gene-therapies Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/activist-investor-starboard-cries-foul-play-in-exec-u-turn-at-pfizer https://spypharm.com/activist-investor-starboard-cries-foul-play-in-exec-u-turn-at-pfizer Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/keybioscience-and-eli-lilly-extend-partnership-for-obesity-treatments https://spypharm.com/keybioscience-and-eli-lilly-extend-partnership-for-obesity-treatments Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/cphi-europe-overcoming-the-unique-challenges-with-high-concentration-mabs https://spypharm.com/cphi-europe-overcoming-the-unique-challenges-with-high-concentration-mabs Sat, 12 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/fda-adcom-votes-in-favour-of-stealths-barth-syndrome-drug https://spypharm.com/fda-adcom-votes-in-favour-of-stealths-barth-syndrome-drug Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/south-korean-company-dong-a-st-wins-fda-approval-for-stelara-biosimilar https://spypharm.com/south-korean-company-dong-a-st-wins-fda-approval-for-stelara-biosimilar Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/global-awareness-and-geographic-variations-of-plaque-psoriasis https://spypharm.com/global-awareness-and-geographic-variations-of-plaque-psoriasis Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/roche-wins-first-line-approval-for-pi3k-inhibitor-combo-in-breast-cancer https://spypharm.com/roche-wins-first-line-approval-for-pi3k-inhibitor-combo-in-breast-cancer Sat, 12 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/city-therapeutics-launches-with-135m-series-a-funding https://spypharm.com/city-therapeutics-launches-with-135m-series-a-funding Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/ipsens-elafibranor-gains-mhra-approval-for-pbc-treatment https://spypharm.com/ipsens-elafibranor-gains-mhra-approval-for-pbc-treatment Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/magazine-cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing https://spypharm.com/magazine-cell-and-gene-therapy-approvals-drive-paradigm-change-in-manufacturing Thu, 10 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/could-preventative-care-save-the-future-of-the-nhs https://spypharm.com/could-preventative-care-save-the-future-of-the-nhs Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/emergent-to-donate-20000-narcan-doses-to-fight-opioid-overdoses-ceo-says https://spypharm.com/emergent-to-donate-20000-narcan-doses-to-fight-opioid-overdoses-ceo-says Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/fda-declines-to-approve-zealand-pharmas-hypoglycaemia-therapy-in-infants https://spypharm.com/fda-declines-to-approve-zealand-pharmas-hypoglycaemia-therapy-in-infants Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/purespring-secures-105m-to-start-phase-iii-trial-of-igan-gene-therapy https://spypharm.com/purespring-secures-105m-to-start-phase-iii-trial-of-igan-gene-therapy Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/clinical-dose-companies-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/clinical-dose-companies-in-contract-manufacturing-for-the-pharmaceutical-industry Thu, 10 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/anima-biotechs-machine-learning-programme-reveals-new-mrna-drug-targets https://spypharm.com/anima-biotechs-machine-learning-programme-reveals-new-mrna-drug-targets Thu, 10 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/msd-ventures-into-fibroblast-therapies-with-19bn-deal-with-mestag https://spypharm.com/msd-ventures-into-fibroblast-therapies-with-19bn-deal-with-mestag Thu, 10 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/mrna-licensing-agreements-double-with-million-dollar-deals https://spypharm.com/mrna-licensing-agreements-double-with-million-dollar-deals Tue, 08 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/neuvivo-makes-bid-to-enter-als-arena-with-immunotherapy-candidate https://spypharm.com/neuvivo-makes-bid-to-enter-als-arena-with-immunotherapy-candidate Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/productlife-boosts-drug-development-with-intiquan-acquisition https://spypharm.com/productlife-boosts-drug-development-with-intiquan-acquisition Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/health-canada-approves-telixs-illuccix-label-expansion https://spypharm.com/health-canada-approves-telixs-illuccix-label-expansion Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/onkure-and-reneo-pharmaceuticals-complete-merger https://spypharm.com/onkure-and-reneo-pharmaceuticals-complete-merger Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/nuhss-cd7-car-t-cell-therapy-shows-promise-for-leukaemia https://spypharm.com/nuhss-cd7-car-t-cell-therapy-shows-promise-for-leukaemia Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/ema-starts-review-into-hair-loss-drugs-about-potential-link-to-suicidal-thoughts https://spypharm.com/ema-starts-review-into-hair-loss-drugs-about-potential-link-to-suicidal-thoughts Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/oncolytics-targets-accelerated-approval-for-oncolytic-virus-therapy https://spypharm.com/oncolytics-targets-accelerated-approval-for-oncolytic-virus-therapy Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/activist-investor-starboard-forges-1bn-stake-in-pfizer-to-swing-profits https://spypharm.com/activist-investor-starboard-forges-1bn-stake-in-pfizer-to-swing-profits Tue, 08 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/teva-and-mabxience-partner-to-develop-biosimilar-candidate-for-oncology https://spypharm.com/teva-and-mabxience-partner-to-develop-biosimilar-candidate-for-oncology Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/bms-receives-fda-approval-for-opdivo-to-treat-nsclc https://spypharm.com/bms-receives-fda-approval-for-opdivo-to-treat-nsclc Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/resilience-secures-funds-to-enhance-production-of-essential-medicine-components https://spypharm.com/resilience-secures-funds-to-enhance-production-of-essential-medicine-components Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/a-rational-design-approach-to-rna-targeting-could-replace-large-scale-screening https://spypharm.com/a-rational-design-approach-to-rna-targeting-could-replace-large-scale-screening Sun, 06 Oct 2024 04:00:17 -0400 spectro https://spypharm.com/editas-trades-part-of-vertex-crispr-therapy-licencing-rights-deal-for-57m https://spypharm.com/editas-trades-part-of-vertex-crispr-therapy-licencing-rights-deal-for-57m Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/wuxi-debates-sale-of-pharma-operations-as-biosecure-act-advances https://spypharm.com/wuxi-debates-sale-of-pharma-operations-as-biosecure-act-advances Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/the-benefits-of-using-a-nimble-platform-from-phase-to-phase https://spypharm.com/the-benefits-of-using-a-nimble-platform-from-phase-to-phase Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/nhs-proposes-phased-launch-for-eli-lillys-mounjaro https://spypharm.com/nhs-proposes-phased-launch-for-eli-lillys-mounjaro Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/fda-lifts-clinical-hold-on-aviditys-lead-antibody-conjugate-therapy-trial https://spypharm.com/fda-lifts-clinical-hold-on-aviditys-lead-antibody-conjugate-therapy-trial Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/recordati-to-acquire-worldwide-rights-to-sanofis-antibody-enjaymo https://spypharm.com/recordati-to-acquire-worldwide-rights-to-sanofis-antibody-enjaymo Sun, 06 Oct 2024 04:00:16 -0400 spectro https://spypharm.com/social-media-algorithms-are-driving-the-glp-1-drugs-boom https://spypharm.com/social-media-algorithms-are-driving-the-glp-1-drugs-boom Fri, 04 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/gilead-signs-agreements-to-facilitate-access-to-hiv-prevention-drug https://spypharm.com/gilead-signs-agreements-to-facilitate-access-to-hiv-prevention-drug Fri, 04 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/eli-lilly-to-invest-45bn-for-drug-manufacturing-and-trial-medicine-production https://spypharm.com/eli-lilly-to-invest-45bn-for-drug-manufacturing-and-trial-medicine-production Fri, 04 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/immunoprecise-and-biotheus-partner-on-bispecific-antibodies-to-treat-cancer https://spypharm.com/immunoprecise-and-biotheus-partner-on-bispecific-antibodies-to-treat-cancer Fri, 04 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/novaliq-and-laboratoires-thea-announce-ec-approval-for-dry-eye-disease-therapy https://spypharm.com/novaliq-and-laboratoires-thea-announce-ec-approval-for-dry-eye-disease-therapy Fri, 04 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/resolution-scores-83m-to-develop-macrophage-cell-therapies https://spypharm.com/resolution-scores-83m-to-develop-macrophage-cell-therapies Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/enara-bio-secures-325m-for-dark-antigen-cancer-therapies https://spypharm.com/enara-bio-secures-325m-for-dark-antigen-cancer-therapies Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/healthcare-payers-for-the-pharmaceutical-industry https://spypharm.com/healthcare-payers-for-the-pharmaceutical-industry Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/a-rational-design-approach-to-rna-targeting-to-target-large-scale-screening https://spypharm.com/a-rational-design-approach-to-rna-targeting-to-target-large-scale-screening Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/chronic-diseases-as-urgent-as-climate-change-says-novo-nordisk-cso https://spypharm.com/chronic-diseases-as-urgent-as-climate-change-says-novo-nordisk-cso Fri, 04 Oct 2024 04:00:07 -0400 spectro https://spypharm.com/bms-and-prime-ink-potential-35bn-deal-to-develop-t-cell-therapies https://spypharm.com/bms-and-prime-ink-potential-35bn-deal-to-develop-t-cell-therapies Wed, 02 Oct 2024 04:00:12 -0400 spectro https://spypharm.com/speciality-chemicals-for-the-pharmaceutical-industry https://spypharm.com/speciality-chemicals-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/ascendis-pharma-submits-sbla-for-growth-hormone-deficiency-therapy https://spypharm.com/ascendis-pharma-submits-sbla-for-growth-hormone-deficiency-therapy Wed, 02 Oct 2024 04:00:11 -0400 spectro https://spypharm.com/specialty-pharmacies-for-the-pharmaceutical-industry https://spypharm.com/specialty-pharmacies-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/fresenius-kabi-wins-fda-approval-for-stelara-biosimilar-otulfi https://spypharm.com/fresenius-kabi-wins-fda-approval-for-stelara-biosimilar-otulfi Wed, 02 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/robotics-companies-manufacturers-for-the-pharmaceutical-industry https://spypharm.com/robotics-companies-manufacturers-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:10 -0400 spectro https://spypharm.com/medication-adherence-solutions-for-the-pharmaceutical-industry https://spypharm.com/medication-adherence-solutions-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:09 -0400 spectro https://spypharm.com/genentech-buys-regors-cdk-inhibitors-in-850m-deal https://spypharm.com/genentech-buys-regors-cdk-inhibitors-in-850m-deal Wed, 02 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/the-course-to-forging-long-term-manufacturing-partnerships-for-gene-therapies https://spypharm.com/the-course-to-forging-long-term-manufacturing-partnerships-for-gene-therapies Wed, 02 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/sterilisation-solutions-equipment-and-services-for-the-pharmaceutical-industry https://spypharm.com/sterilisation-solutions-equipment-and-services-for-the-pharmaceutical-industry Wed, 02 Oct 2024 04:00:08 -0400 spectro https://spypharm.com/blockchain-leaders-finesse-tech-to-find-fake-drugs https://spypharm.com/blockchain-leaders-finesse-tech-to-find-fake-drugs Mon, 30 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-medidata-wins-awards-forclinical-data-studio-and-health-record-connect https://spypharm.com/pharmaceutical-technology-excellence-awards-2024-medidata-wins-awards-forclinical-data-studio-and-health-record-connect Mon, 30 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/tempus-ai-expands-oncology-collaboration-with-takeda https://spypharm.com/tempus-ai-expands-oncology-collaboration-with-takeda Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/phare-bio-receives-arpa-h-funds-for-ai-drug-discovery-platform https://spypharm.com/phare-bio-receives-arpa-h-funds-for-ai-drug-discovery-platform Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/physicians-highlight-need-for-improved-non-opioid-treatments-for-opioid-use-disorder https://spypharm.com/physicians-highlight-need-for-improved-non-opioid-treatments-for-opioid-use-disorder Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/direct-to-patient-communication-bridging-the-gap-in-medication-adherence https://spypharm.com/direct-to-patient-communication-bridging-the-gap-in-medication-adherence Sat, 28 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/bms-wins-approval-for-schizophrenia-drug-acquired-from-karuna https://spypharm.com/bms-wins-approval-for-schizophrenia-drug-acquired-from-karuna Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/unicef-secures-one-million-mpox-vaccines-for-africa https://spypharm.com/unicef-secures-one-million-mpox-vaccines-for-africa Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/biomeas-stock-bounces-back-as-fda-lifts-clinical-hold-on-diabetes-trials https://spypharm.com/biomeas-stock-bounces-back-as-fda-lifts-clinical-hold-on-diabetes-trials Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/api-chemical-contract-manufacturing-companies-for-the-pharmaceutical-industry https://spypharm.com/api-chemical-contract-manufacturing-companies-for-the-pharmaceutical-industry Sat, 28 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/fda-greenlights-regenerons-dupixent-for-the-treatment-of-copd https://spypharm.com/fda-greenlights-regenerons-dupixent-for-the-treatment-of-copd Sat, 28 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/sanofiregenerons-dupixent-set-to-dominate-copd-biologics-market-following-fda-approval https://spypharm.com/sanofiregenerons-dupixent-set-to-dominate-copd-biologics-market-following-fda-approval Sat, 28 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/bavarian-nordic-gains-us-contract-for-additional-mpox-vaccine https://spypharm.com/bavarian-nordic-gains-us-contract-for-additional-mpox-vaccine Thu, 26 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/generatebiomedicines-and-novartis-link-on-protein-therapeutics-development https://spypharm.com/generatebiomedicines-and-novartis-link-on-protein-therapeutics-development Thu, 26 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/biotechnology-equipment-manufacturers-companies-and-suppliers-for-the-pharmaceutical-industry https://spypharm.com/biotechnology-equipment-manufacturers-companies-and-suppliers-for-the-pharmaceutical-industry Thu, 26 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/biologic-api-manufacturing-companies-protein-and-peptide-in-contract-manufacturing-for-the-pharmaceutical-industry https://spypharm.com/biologic-api-manufacturing-companies-protein-and-peptide-in-contract-manufacturing-for-the-pharmaceutical-industry Thu, 26 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/oral-solid-dose-manufacturing-companies-in-the-pharmaceutical-industry https://spypharm.com/oral-solid-dose-manufacturing-companies-in-the-pharmaceutical-industry Thu, 26 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/genespire-raises-52m-in-series-b-to-trial-paediatric-gene-therapy https://spypharm.com/genespire-raises-52m-in-series-b-to-trial-paediatric-gene-therapy Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/managing-temperature-sensitive-injectable-drugs-in-fill-finish-operations https://spypharm.com/managing-temperature-sensitive-injectable-drugs-in-fill-finish-operations Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/why-a-new-prescription-tracking-feature-on-the-nhs-app-is-important-for-pharmacists https://spypharm.com/why-a-new-prescription-tracking-feature-on-the-nhs-app-is-important-for-pharmacists Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/epigenetic-drugs-show-375-increase-in-series-a-venture-financing-in-2024 https://spypharm.com/epigenetic-drugs-show-375-increase-in-series-a-venture-financing-in-2024 Thu, 26 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/teva-touts-safety-profile-of-once-monthly-schizophrenia-therapy https://spypharm.com/teva-touts-safety-profile-of-once-monthly-schizophrenia-therapy Tue, 24 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i https://spypharm.com/vicebio-secures-100m-to-advance-rsv-and-hmpv-vaccine-combo-to-phase-i Tue, 24 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/pharmaceutical-wholesalers-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-wholesalers-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/ipsens-iqirvo-wins-european-approval-for-primary-biliary-cholangitis https://spypharm.com/ipsens-iqirvo-wins-european-approval-for-primary-biliary-cholangitis Tue, 24 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/pharmaceutical-automation-and-equipment-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-automation-and-equipment-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/pharmaceutical-logistics-companies-and-supply-chain-specialists-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-logistics-companies-and-supply-chain-specialists-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/sanofi-gains-exclusivity-rights-to-ventyxs-cns-penetrant-drug-in-27m-deal https://spypharm.com/sanofi-gains-exclusivity-rights-to-ventyxs-cns-penetrant-drug-in-27m-deal Tue, 24 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/pancreatic-cancer-the-clinical-trial-landscape-and-progress-for-2024 https://spypharm.com/pancreatic-cancer-the-clinical-trial-landscape-and-progress-for-2024 Tue, 24 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/pharmaceutical-compliance-management-software-for-the-pharmaceutical-industry https://spypharm.com/pharmaceutical-compliance-management-software-for-the-pharmaceutical-industry Tue, 24 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/pharmaceutical-packaging-machines-and-labelling-companies https://spypharm.com/pharmaceutical-packaging-machines-and-labelling-companies Sun, 22 Sep 2024 04:00:11 -0400 spectro https://spypharm.com/clinical-development-services-for-clinical-trials https://spypharm.com/clinical-development-services-for-clinical-trials Sun, 22 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/pharmaceutical-product-testing-inspection-and-detection-equipment-and-services https://spypharm.com/pharmaceutical-product-testing-inspection-and-detection-equipment-and-services Sun, 22 Sep 2024 04:00:10 -0400 spectro https://spypharm.com/non-sterile-pharmaceutical-manufacturing-companies-commercial-dose-for-the-pharmaceutical-industry https://spypharm.com/non-sterile-pharmaceutical-manufacturing-companies-commercial-dose-for-the-pharmaceutical-industry Sun, 22 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/ema-approves-bavarian-nordics-mpox-vaccine-for-teenagers https://spypharm.com/ema-approves-bavarian-nordics-mpox-vaccine-for-teenagers Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/gc-therapeutics-secures-65m-to-launch-into-off-the-shelf-ipsc-therapy-space https://spypharm.com/gc-therapeutics-secures-65m-to-launch-into-off-the-shelf-ipsc-therapy-space Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/sanofi-eyes-approval-after-ms-therapy-slows-disease-progression-by-31 https://spypharm.com/sanofi-eyes-approval-after-ms-therapy-slows-disease-progression-by-31 Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/magazine-enhancing-therapy-adherence-with-prodrugs https://spypharm.com/magazine-enhancing-therapy-adherence-with-prodrugs Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/commercial-drug-manufacturing-companies-for-the-pharmaceutical-industry https://spypharm.com/commercial-drug-manufacturing-companies-for-the-pharmaceutical-industry Sun, 22 Sep 2024 04:00:08 -0400 spectro https://spypharm.com/ai-boom-set-to-revolutionise-healthcare-in-europe https://spypharm.com/ai-boom-set-to-revolutionise-healthcare-in-europe Sun, 22 Sep 2024 04:00:07 -0400 spectro https://spypharm.com/lupin-and-takeda-to-commercialise-vonoprazan-in-india https://spypharm.com/lupin-and-takeda-to-commercialise-vonoprazan-in-india Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/fda-approves-accord-biopharmas-hercessi-for-cancer-treatment https://spypharm.com/fda-approves-accord-biopharmas-hercessi-for-cancer-treatment Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/gavi-to-obtain-500000-mpox-vaccine-doses-from-bavarian-nordic https://spypharm.com/gavi-to-obtain-500000-mpox-vaccine-doses-from-bavarian-nordic Fri, 20 Sep 2024 04:00:09 -0400 spectro https://spypharm.com/fda-approves-msds-keytruda-as-first-line-mpm-treatment https://spypharm.com/fda-approves-msds-keytruda-as-first-line-mpm-treatment Fri, 20 Sep 2024 04:00:09 -0400 spectro